X4P-001 + axitinib
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma
Trial Timeline
Apr 27, 2016 → Apr 14, 2022
NCT ID
NCT02667886About X4P-001 + axitinib
X4P-001 + axitinib is a phase 1/2 stage product being developed by X4 Pharmaceuticals for Clear Cell Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02667886. Target conditions include Clear Cell Renal Cell Carcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02667886 | Phase 1/2 | Completed |
Competing Products
20 competing products in Clear Cell Renal Cell Carcinoma